Chatham Capital Group, Inc. Abb Vie Inc. Transaction History

Chatham Capital Group, Inc.

$601 Million
Q3 2024

A detailed history of Chatham Capital Group, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Chatham Capital Group, Inc. holds 36,112 shares of ABBV stock, worth $6.5 Million. This represents 1.19% of its overall portfolio holdings.

Number of Shares

36,112

Previous 32,127 12.4%

Holding current value

$6.5 Million

Previous $5.51 Million 29.42%

% of portfolio

1.19%

Previous 0.97%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	BUY	$163.84 - $199.33 $652,902 - $794,330	3,985 Added 12.4%	36,112 $7.13 Million
Q2 2024 Jul 15, 2024	BUY	$154.79 - $180.76 $158,195 - $184,736	1,022 Added 3.29%	32,127 $5.51 Million
Q1 2024 Apr 17, 2024	SELL	$159.82 - $182.1 $14,863 - $16,935	-93 Reduced 0.3%	31,105 $5.66 Million
Q4 2023 Jan 19, 2024	SELL	$137.6 - $154.97 $67,424 - $75,935	-490 Reduced 1.55%	31,198 $4.83 Million
Q3 2023 Oct 25, 2023	SELL	$133.59 - $154.65 $22,443 - $25,981	-168 Reduced 0.53%	31,688 $4.72 Million
Q2 2023 Jul 13, 2023	SELL	$132.51 - $164.9 $53,004 - $65,960	-400 Reduced 1.24%	31,856 $4.29 Million
Q1 2023 Apr 21, 2023	SELL	$144.61 - $166.54 $146,779 - $169,038	-1,015 Reduced 3.05%	32,256 $5.14 Million
Q4 2022 Jan 31, 2023	SELL	$138.31 - $165.87 $1.11 Million - $1.33 Million	-8,043 Reduced 19.47%	33,271 $5.38 Million
Q3 2022 Oct 28, 2022	SELL	$134.21 - $153.93 $8,186 - $9,389	-61 Reduced 0.15%	41,314 $5.55 Million
Q2 2022 Aug 02, 2022	SELL	$137.62 - $174.96 $23,120 - $29,393	-168 Reduced 0.4%	41,375 $6.34 Million
Q1 2022 Apr 21, 2022	SELL	$131.98 - $163.75 $318,731 - $395,456	-2,415 Reduced 5.49%	41,543 $6.73 Million
Q4 2021 Feb 02, 2022	SELL	$107.43 - $135.93 $276,632 - $350,019	-2,575 Reduced 5.53%	43,958 $5.95 Million
Q3 2021 Oct 13, 2021	SELL	$106.4 - $120.78 $441,347 - $500,995	-4,148 Reduced 8.18%	46,533 $5.02 Million
Q2 2021 Jul 28, 2021	SELL	$105.21 - $117.21 $260,079 - $289,743	-2,472 Reduced 4.65%	50,681 $5.71 Million
Q1 2021 Apr 29, 2021	SELL	$102.3 - $112.62 $340,147 - $374,461	-3,325 Reduced 5.89%	53,153 $5.75 Million
Q4 2020 Jan 27, 2021	SELL	$80.49 - $108.67 $7,727 - $10,432	-96 Reduced 0.17%	56,478 $6.05 Million
Q3 2020 Oct 22, 2020	SELL	$85.91 - $100.83 $228,520 - $268,207	-2,660 Reduced 4.49%	56,574 $4.96 Million
Q2 2020 Jul 20, 2020	SELL	$73.37 - $98.18 $181,590 - $242,995	-2,475 Reduced 4.01%	59,234 $5.82 Million
Q1 2020 May 01, 2020	SELL	$64.5 - $97.79 $5,160 - $7,823	-80 Reduced 0.13%	61,709 $4.7 Million
Q4 2019 Jan 31, 2020	SELL	$72.13 - $90.25 $78,621 - $98,372	-1,090 Reduced 1.73%	61,789 $5.47 Million
Q3 2019 Nov 08, 2019	SELL	$62.98 - $75.72 $346,390 - $416,460	-5,500 Reduced 8.04%	62,879 $4.76 Million
Q2 2019 Jul 24, 2019	SELL	$65.7 - $83.98 $62,743 - $80,200	-955 Reduced 1.38%	68,379 $4.97 Million
Q1 2019 May 09, 2019	SELL	$77.14 - $90.79 $212,135 - $249,672	-2,750 Reduced 3.81%	69,334 $5.59 Million
Q4 2018 Feb 06, 2019	SELL	$77.85 - $96.01 $358,110 - $441,646	-4,600 Reduced 6.0%	72,084 $6.65 Million
Q3 2018 Oct 30, 2018	BUY	$88.91 - $98.84 $66,682 - $74,130	750 Added 0.99%	76,684 $7.25 Million
Q2 2018 Jul 30, 2018	SELL	$89.78 - $106.23 $6,733 - $7,967	-75 Reduced 0.1%	75,934 $7.04 Million
Q1 2018 May 09, 2018	SELL	$92.01 - $123.21 $219,443 - $293,855	-2,385 Reduced 3.04%	76,009 $7.19 Million
Q4 2017 Feb 01, 2018	SELL	$89.56 - $98.21 $137,922 - $151,243	-1,540 Reduced 1.93%	78,394 $7.58 Million
Q3 2017 Nov 08, 2017	SELL	$69.85 - $89.22 $127,825 - $163,272	-1,830 Reduced 2.24%	79,934 $7.1 Million
Q2 2017 Aug 09, 2017	BUY	N/A	81,764	81,764 $5.93 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chatham Capital Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chatham Capital Group, Inc. with notifications on news.

Account

Chatham Capital Group, Inc. Abb Vie Inc. Transaction History